Conditional PIK3CA H1047R Mouse Model for Breast Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for studying PIK3CA mutations in breast cancer lack a reliable, genetically engineered mouse model that can express endogenous levels of mutant PIK3CA from its native promoter, limiting understanding of tumor initiation, progression, and treatment strategies.
Innovation Solution
A genetically engineered mouse model with a modified PIK3CA locus allowing conditional expression of the PIK3CA H1047R mutant allele, activated by Cre-mediated recombination, which mimics the native promoter and genomic architecture, enabling the study of tumor initiation and progression, and identification of cooperating lesions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cell-based systems or xenograft models are used to study PIK3CA mutations, then tumor formation can be observed, but the model cannot express endogenous levels of mutant PIK3CA from its native promoter and genomic architecture
Solution Approach 1:
The PIK3CA gene is divided into two alleles: one wild-type allele and one mutant allele with the H1047R mutation. The mutant allele is placed in a dormant state flanked by loxP sites, while the wild-type allele remains active. This segmentation allows controlled expression of the mutant protein only in specific tissues and time points, resolving the contradiction between model reliability and complexity by enabling precise spatial and temporal control of oncogene expression.
Solution Approach 2:
The mouse model is pre-engineered with the dormant mutant PIK3CA allele integrated into the endogenous genomic locus before tumor induction. The mutant allele is prepared in a latent state with loxP sites, ready for activation by Cre recombinase. This preliminary preparation allows the model to express endogenous levels of mutant PIK3CA from its native promoter when activated, improving reliability without requiring complex external intervention during tumor formation studies.
2Manufacturing precision
If a knock-in mouse model with conditional expression is created, then endogenous levels of mutant PIK3CA can be expressed from the native promoter, but the genetic engineering complexity increases
Solution Approach 1:
The mutant PIK3CA allele is integrated specifically at the endogenous PIK3CA locus on chromosome 7, replacing the native sequence with the mutant version flanked by loxP sites. This local modification ensures that the mutant allele is expressed only from its native promoter in the appropriate tissue context (mammary epithelium under MMTV-Cre control), achieving precise spatial and temporal expression without requiring complex global genetic modifications throughout the genome.
Solution Approach 2:
Cre recombinase acts as an intermediary to activate the dormant mutant PIK3CA allele. The loxP sites serve as recognition sequences for Cre, which catalyzes recombination to remove the transcriptional stop cassette and activate mutant allele expression. This intermediary mechanism provides clean, binary control over mutant gene expression without requiring complex regulatory elements or multiple transgenic components, resolving the contradiction between expression precision and engineering complexity.
3Adaptability or versatility
If multiple genetic modifications are introduced to study tumor initiation and progression, then comprehensive tumor models can be created, but the difficulty of detecting and measuring spontaneous mutations increases
Solution Approach 1:
The patent extracts and analyzes specific genomic regions of interest from the complex tumor genome, focusing on the PIK3CA locus and surrounding areas. By using targeted sequencing approaches rather than analyzing the entire genome, the model enables detection of spontaneous mutations like TP53 R248H even in the presence of the engineered PIK3CA modification. This extraction approach reduces the complexity of mutation detection while maintaining comprehensive tumor modeling capabilities.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The model successfully induces breast tumors with multiple histological types, allowing for the identification of spontaneous mutations like TP53 R248H, and demonstrates responsiveness to PI3K inhibitors, providing a valuable tool for understanding tumor development and treatment efficacy.
Implementation Method 1
upon Cre-mediated recombination the mutant PIK3CA H1047R allele, PIK3CA e20H1047R is activated leading to its expression
Data Source
Figure 1A~1C
Figure 1D~1E
Figure 1F~1I
AI summary
The invention concerns the development of a PIK3CA H1047R knock-in non-human animal breast cancer model, and its use for identification of a spontaneous loss-of-function TP53 mutation involved in spindle cell tumor formation. The invention further concerns the identification of additional somatic mutations and copy number aberrations in the breast tumors using this model, and methods and means for the diagnosis and treatment of breast cancer.